Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence. December 8, 2025 Recursion Pharma's ...

Lindsey Ellefson is Lifehacker’s Features Editor. She currently covers study and productivity hacks, as well as household and digital decluttering, and oversees the freelancers on the sex and ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The Java Scanner class provides methods that take String input and convert that String into any ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...